REG - Trellus Health PLC - Directorate Change

Trellus HealthAnnouncement

19/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240919:nRSS7746Ea&default-theme=true

RNS Number : 7746E  Trellus Health PLC  19 September 2024

Trellus Health plc

("Trellus Health" or the "Company")

 

Directorate Change

 

LONDON, U.K. AND NEW YORK, U.S. (19 September 2024). Trellus Health plc (AIM:
TRLS), a healthcare company delivering innovative, scientifically validated
programs and technologies designed to facilitate the better management of
chronic conditions, improve health outcomes and lower the costs of care,
announces the appointment of Brian Griffin as Non-Executive Director with
immediate effect.

 

Mr Griffin is an experienced healthcare executive with over 40 years of senior
leadership and operational experience in various healthcare sectors, including
at multiple Fortune 500 companies, with particular expertise in managed care.
He currently serves as Chief Executive Officer for Advanced Dermatology and
Cosmetic surgery, a leading physician-led dermatology practice in the United
States, with more than 150 offices in 14 states.

 

Prior to this, Mr Griffin served as Chairman and Chief Executive Officer at
Diplomat Pharmacy Inc. (NYSE: DPLO), the largest independent specialty
pharmacy and pharmacy benefit manager in the United States, until it was
acquired by Optum Rx, a subsidiary of UnitedHealth Group, in February 2020. Mr
Griffin also spent over five years at Anthem, Inc. (now called Elevance
Health), an American health insurance provider, where he led their $40bn+
revenue Commercial and Speciality businesses, including Anthem's 14 national
Blue Cross and Blue Shield Plans. Previously, Brian also spent 25 years at
Medco Health Solutions, later Merck Medco, from 1988, where he was appointed
to senior executive roles at several Medco subsidiaries, and he led the
creation of Medco's international business.

 

As part of his role, Brian will also serve as Chair of the Audit Committee.

 

Dr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said: "I am
very pleased to welcome Brian to the Board of Trellus Health. Brian has
extensive experience across the US managed care industry, particularly in the
managed care and speciality pharmacy segments, gained over the course of his
career, which is the exact skillset that we have been looking to appoint on
our Board. This makes him a great fit for us as we build commercial traction
and aim to improve the lives of as many people living with IBD and other
chronic conditions as possible."

 

Brian Griffin, Non-Executive Director of Trellus Health, said: "I am
passionate about services that can improve patient outcomes and lower the
costs of care, and Trellus Health's solution has been proven to achieve both.
I believe my experience within managed care and pharmacy sectors can help the
Company as it continues to commercialise its approach to chronic condition
management, and I look forward to working with the rest of the Board."

 

Regulatory Disclosures

 

Save for the information set out above and below, there are no further
disclosures to be made in accordance with Rule 17, Schedule Two (g) of the AIM
Rules for Companies in respect of the appointment of Mr Brian Thomas Griffin,
aged 65.

 

 Current Directorships                              Past Directorships (previous 5 years)
 Advanced Dermatology & Cosmetic Surgery, Inc.      Diplomat Pharmacy, Inc.

 Nimble Health, LLC                                 CRH Medical Corporation

 Nox Health Group, Inc.                             Healthcare Services Acquisition Corporation

 YourCoach, Inc.                                    Visiting Nurses Association Health Group

 LucyRx

 

 

For further information please contact:

 

 Trellus Health plc                                                          https://trellushealth.com/ (https://trellushealth.com/)
 Dr. Marla Dubinsky, CEO and Co-Founder                                      Via Walbrook PR
 Joy Bessenger, CFO

 Singer Capital Markets (Nominated Adviser and Broker)                       Tel: +44 (0)20 7496 3000
 Jen Boorer / James Todd / Jalini Kalaravy

 Walbrook PR                                  Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                                              (mailto:trellus@walbrookpr.com)
 Paul McManus / Sam Allen / Phillip Marriage  Mob: +44 (0)7980 541 893 / 07748 651 727 / 07867 984 082

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

Trellus Health (AIM: TRLS) is a healthcare company providing value-based
innovative solutions and services for chronic condition management that
prioritises improved outcomes and member experiences while managing costs of
care.

 

Trellus Health integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate™, a whole-person technology-enhanced experience that meets
each individual's unique needs and empowers them to master their physical and
emotional health. Trellus Elevate's™ clinically proven solutions result in
relieving disease burden, building self-management skills and promoting
positive health behaviours that improve outcomes and enables thriving in the
face of a chronic condition.

 

The Company's proven whole person approach recognises the interconnectedness
of various aspects of a person's life and aims to address the whole spectrum
of factors that influence behaviour, to promote comprehensive well-being and
human flourishing in a way that aligns with value-based care. Trellus Health's
approach enables better health outcomes in a member-centric, personalised and
comprehensive holistic solution.

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD
and Laurie Keefer, PhD, both experts at treating and healing both the physical
and emotional impacts of IBD and have been innovators for whole-person
healthcare for a combined 50 years.

 

The Company is initially focusing on chronic costly GI conditions that have
high mental health burden, such as inflammatory bowel disease ("IBD") which
includes the chronic incurable conditions of Crohn's Disease and ulcerative
colitis. Given the common emotional and mental health struggles often
experienced by individuals suffering from a variety of chronic conditions,
Trellus Health considers its approach to have potential utility and demand
across many conditions.

 

The Trellus Elevate™ program incorporates the GRITT™ methodology and
learnings on resilience from clinical research and practice conducted at the
Mount Sinai IBD Center for more than seven years. This proprietary,
resilience-driven methodology has been scientifically validated to demonstrate
meaningful improvements in patient outcomes, 71% reduction in Emergency
Department (A&E) visits, and 94% reduction in unplanned hospitalisations,
which the directors of the Company believe indicates the potential for
significant cost savings for healthcare payers and health systems. Patients
with IBD managed with the proprietary resilience methodology also experienced
a 49% reduction in required opioid use and a 73% reduction in corticosteroid
use 12 months following starting the program which is a major indicator of
improved health outcomes(1.)

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information on Trellus Health, visit:
www.trellushealth.com (http://www.trellushealth.com)

 

(1) Source:
https://www.sciencedirect.com/science/article/pii/S1542356521012258
(https://www.sciencedirect.com/science/article/pii/S1542356521012258)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABIGDCIBBDGSI